GlassScriptPhysician profile
Gilbert W Leung
NPI 1528117314
$6,061.06
in general payments reported to CMS, 2019-2025
33 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $657 · 2021: $552 · 2022: $1,034 · 2023: $1,205 · 2024: $903 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,203.30 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $844.29 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.51 | 2019-2025 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $460.98 | 2019-2023 | |
| Lilly USA, LLC | $452.24 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $425.76 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $312.97 | 2019-2025 | |
| Abbvie INC. | $307.38 | 2021-2025 | |
| Gilead Sciences, INC. | $299.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $228.12 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $178.99 | 2021-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $147.29 | 2019-2023 | |
| Exact Sciences Corporation | $73.74 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $70.91 | 2022-2025 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $62.09 | 2020-2023 | Seglentis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $57.71 | 2019-2022 | |
| Amarin Pharma, INC. | $41.87 | 2019-2021 | |
| Almatica Pharma LLC | $41.42 | 2021-2022 | |
| Allergan, INC. | $39.06 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.51 | 2021-2024 | |
| Globus Medical, INC. | $30.58 | 2025 | Senza |
| Horizon Therapeutics Plc | $22.06 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $21.67 | 2025 | Gemtesa |
| Mannkind Corporation | $20.50 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.09 | 2023 | Opsumit, Uptravi |
| Redhill Biopharma INC. | $17.89 | 2020 | |
| Global Blood Therapeutics, INC. | $17.70 | 2022 | |
| Janssen Biotech, INC. | $17.28 | 2021 | |
| Ibsa Pharma INC. | $17.08 | 2023 | Tirosint, Licart |
| Insightec,INC | $16.91 | 2025 | Exablate |
| Dexcom, INC. | $15.65 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $15.43 | 2025 | Flucelvax, Fluad |
| Alvogen INC | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.